Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company, quotes POAI CEO Dr. Carl Schwartz, where he states, “This acquisition will enable us … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Integrate Proprietary Database with CoRE to Drive Drug Discovery, Development”
POAI’s TumorGenesis inks deal with top-rated medical university in New England Predictive’s proprietary media allows researchers around the world to isolate, culture ovarian cancer cell types, leading to new targets for treatment The TumorGenesis media retain more than 95% of the DNA and RNA as well as crucial proteomic signatures Predictive Oncology (NASDAQ: POAI) has … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Announces First Commercial Sale of Unique Ovarian-Cancer-Cell Media”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is on a well-funded path to move forward with its goals. A recent article discussing this quotes POAI CEO Dr. Carl Schwartz, who states, “[POAI] improved our liquidity position and streamlined our capital structure with the … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) on ‘Cash Runway’ to Fund Key Milestones”
POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates Company to offer new capability to pharmaceutical company customers in revenue-generating projects later this year Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Finalizes Acquisition Deal Expected to Revolutionize Role of AI-Driven Predictive Models”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of three new members to the company’s board of directors, effective immediately. According to the update, joining the board as independent directors are: Dr. Nancy Chung-Welch, Ph.D., Charles L. Nuzum, CPA and … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Appointments”
POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back” Company closed transaction resulting in gross cash proceeds of approximately $2.2 million Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Releases Q1 2020 Financial, Business Report; Revenues Up, Margins Stay Strong”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. Cofounded by Drs. Robert Murphy and Joshua Kangas, … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC”
Predictive Oncology announced the acquisition of Soluble Therapeutics Inc. & BioDtech Inc. Acquired companies seek to enhance drug development process through the optimization of protein solubility and stability as well as through detection, removal of endotoxins The companies were acquired for consideration amounting to 125,000 common shares and waiving of $1.07 million promissory note issued … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday announced the closing of its previously announced transaction. According to the update, Predictive Oncology secured approximately $2.2 million in gross cash proceeds from the transaction, prior to deducting placement agent fees and offering expenses, … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $2.2M Through Warrant Exercise”
Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is providing clinical decision support tools to support oncologists in personalizing cancer treatment. A recent article discussing the company further reads, “Through its unique patient derived (PDx) platform, which tests the drug response and biomarker profile of the patient’s own tumor, and its vast database of historical … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Leverages Unique Patient-Derived Platform to Assist Oncologists”
